Shire's Strong 2010 Performance Helped By Huge Sales Growth In HGT Business
This article was originally published in The Pink Sheet Daily
Continuing to capitalize on supply problems plaguing rival Genzyme, Shire reported 81% year-over-year sales growth for Fabry disease drug Replagal.
You may also be interested in...
Plus news on recent financings by Ember Therapeutics, Aviir, Covidien and Ariad Pharmaceuticals.
Collaboration will create start-up biotechs to advance promising research in orphan indications, but the companies will not take a “cookie cutter” approach to structure or evolution.
Korea's Green Cross Files For Biobetter Of Shire's Hunter Syndrome Therapy Elaprase; Seeks Global Partners
SEOUL - South Korea's leading vaccine manufacturer Green Cross Corp. took a step forward in the biosimilars sector by submitting a marketing application to Korea FDA for a biobetter of Shire PLC's Elaprase (idursulfase) for Hunter syndrome. And now the company is looking for foreign partners